Emcure Pharmaceuticals buys final 12.05% Gennova stake for ₹231.87 Crore to consolidate control.
Emcure Pharmaceuticals is acquiring the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹231.87 Crore to reach 100% ownership. This move simplifies corporate structure and secures full…
Read the full articleYou might also wanna read
Emcure consolidates stake in Gennova, under stewardship of promoter family scion
Gennova is a ₹49-crore company and it mRNA business, at ₹6.47 crore, represented 0.71% of consolidated revenue of the company of ₹911.58 cro
Emcure subsidiary Gennova to transfer mRNA business to Immunoscript Life Science for ₹139 crore
Gennova brought out India’s first mRNA Covid vaccine
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows
SINGAPORE, July 13 (Reuters) - Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Ind
Merck KGaA acquires Bio-Techne in $11 billion all-cash deal to bolster life sciences division
All-cash deal will strengthen the German company’s life sciences portfolio
cen.acs.org·20d agoGermany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy
Biocon block deal today: Mylan may sell Rs 3,481 crore worth of shares in pharma major
According to Business Today sources, the floor price has been set at Rs 378.50 per share, a 7.9 per cent discount to Biocon's Monday closing
Comments
Sign in to join the conversation.
No comments yet. Be the first.